Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: Results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2)

JACC: Heart Failure

Volumn 1, Issue 4, 2013, Pages 308-314

  Packer, Milton ^a   Carson, Peter ^a   Elkayam, Uri ^a   Konstam, Marvin A ^a   Moe, Gordon ^a   O'Connor, Christopher ^a   Rouleau, Jean Lucien ^a   Schocken, Douglas ^a   Anderson, Susan A ^a   DeMets, David L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

ACE; Amlodipine; Clinical trials; Heart failure; Nonischemic cardiomyopathy; NYHA; PRAISE

Indexed keywords

AMLODIPINE; PLACEBO;

ADULT; ANGINA PECTORIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FAINTNESS; FEMALE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART PALPITATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FUNCTION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONISCHEMIC CARDIOMYOPATHY; PERIPHERAL EDEMA; PRESYNCOPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SURVIVAL; SYSTOLIC BLOOD PRESSURE; THORAX PAIN;

AMLODIPINE; CLINICAL TRIALS; HEART FAILURE; NONISCHEMIC CARDIOMYOPATHY;

AMLODIPINE; CALCIUM CHANNEL BLOCKERS; CARDIOMYOPATHIES; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84881530438     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.04.004     Document Type: Article

References (28)

1. Elkayam U., Amin J., Mehra A., et al. Aprospective randomized, double-blind crossover study to compare the efficacy and safety of chronic nifedipine therapy to isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990, 82:1954-1962.
2. Barjon J.N., Rouleau J.-L., Bichet D., et al. Chronic renal and neurohormonal effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. JAm Coll Cardiol 1987, 9:622-630.
3. Goldstein R.E., Boccuzzi S.J., Cruess D., et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991, 83:52-60.
4. Tan L.B., Murray R.G., Littler W.A. Felodipine in patients with chronic heart failure: discrepant hemodynamic and clinical effects. Br Heart J 1987, 58:122-128.
5. Littler W.A., Sherdian D.J. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Br Heart J 1995, 73:428-433.
6. Packer M. Pathophysiologic mechanisms underlying the adverse effects of calcium channel blocking drugs in patients with chronic heart failure. Circulation 1989, 80(Suppl IV):59-67.
7. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol 2001, 38:2101-2113.
8. Udelson J.E., DeAbate C.A., Berk M., et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am Heart J 2000, 139:503-510.
9. Packer M., O'Connor C.M., Ghali J.K., et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. NEngl J Med 1996, 335:1107-1114. for the Prospective Randomized Amlodipine Survival Evaluation (PRAISE) Study Group.
10. Sole M.J., Liew C.C. Catecholamines, calcium and cardiomyopathy. Am J Cardiol 1988, 62:20G-24G.
11. Weismuller S., Czernin J., Sun K.T., et al. Coronary vasodilatory capacity is impaired in patients with dilated cardiomyopathy. Am J Card Imaging 1996, 10:154-162.
12. Packer M., Meller J., Medina N., et al. Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 1982, 65:660-668.
13. Lan K.K.G., DeMets D.L. Discrete sequential boundaries of clinical trials. Biometrika 1983, 70:59-63.
14. O'Brien P.C., Fleming T.R. Amultiple testing procedure for clinical trials. Biometrics 1979, 35:549-556.
15. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
16. Cox D.R. Regression models and life-tables. JR Stat Soc B 1972, 34:187-202.
17. Feldman A.M., Bristow M.R., Parmley W.W., et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. NEngl J Med 1993, 329:149-155.
18. Cohn J.N., Goldstein S.O., Greenberg B.H., et al. Adose-dependent increase in mortality with vesnarinone among patients with severe heart failure. NEngl J Med 1998, 339:1810-1816.
19. Pitt B., Segal R., Martinez F.A., et al. Randomised trial of losartan versuscaptopril in patients over 65 with heart failure (Evaluation ofLosartan in the Elderly Study, ELITE). Lancet 1997, 349:747-752.
20. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582-1587.
21. Dickstein K., Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction. Lancet 2002, 360:752-760. OPTIMAAL Steering Committee of the OPTIMAAL Study Group.
22. Andresdottir M.B., van Hamersvelt H.W., van Helden M.J., et al. Ankle edema formation during treatment with the calcium channel blockers lacidipine and amlodipine: a single-centre study. JCardiovasc Pharmacol 2000, 35(Suppl 1):S25-S30.
23. Gillmer D.J., Kark P. Pulmonary oedema precipitated by nifedipine. Br Med J 1980, 280:1420-1421.
24. Batra A.K., Segall P.H., Ahmed T. Pulmonary edema with nifedipine in primary pulmonary hypertension. Respiration 1985, 47:161-163.
25. Yoran C., Glassman E. The paradoxical effect of tolazoline hydrochloride on the pulmonary hypertension of mitral stenosis. Chest 1973, 63:843-846.
26. Semigran M.J., Cockrill B.A., Kacmarek R., et al. Hemodynamic effects of inhaled nitric oxide in heart failure. JAm Coll Cardiol 1994, 24:982-988.
27. Haywood G., Sneddon J., Bashin Y., et al. Adenosine infusion for the reversal of pulmonary vasoconstriction in biventricular failure, a good test but a poor therapy. Circulation 1992, 86:896-902.
28. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041. PROGRESS Collaborative Group.